Jubilant Pharmova Limited has submitted newspaper advertisements to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The advertisements were published on April 29, 2026, in Financial Express (English Language – All Editions) and Hindustan & Jansatta (Hindi language), addressing critical shareholder initiatives.

Saksham Niveshak Campaign Details

The company is participating in the second 100 Days Campaign - 'Saksham Niveshak' initiative of the Investor's Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA). This campaign focuses on assisting shareholders in claiming unpaid or unclaimed dividends and updating their Know Your Client (KYC) and nomination details.

Shareholders with outstanding dividends or requiring KYC updates can contact the Company's Registrar and Share Transfer Agent, M/s Alankit Assignments Limited, at Alankit House, 205-208, Anarkali Complex, Jhandewalan Extension, New Delhi - 110055. The RTA can be reached at rta@alankit.com , while shareholders may also contact the company's Nodal Officer at investors@jubi.com .

Special Transfer Window for Physical Shares

In compliance with SEBI Master Circular No. HO/38/13/(4)2026 MIRSD POD/14298/2026 dated February 06, 2026, the company has announced a special window for physical share transfers. This facility continues the initiative previously advertised on February 27, 2026.

The special window accommodates re-lodgement of transfer deeds originally submitted before April 1, 2019 but were rejected, returned, or remained unattended due to documentation or procedural deficiencies. All securities processed under this window will be issued exclusively in dematerialized form and subject to a mandatory one-year lock-in period during which they cannot be transferred, lien marked, or pledged.

Important Exclusions and Requirements

The transfer facility has specific limitations that shareholders must understand:

• Disputed Cases: Matters involving disputes between transferor and transferee are not eligible and must be resolved through appropriate judicial forums such as Courts or NCLT
• IEPF Securities: Securities already transferred to the Investor Education and Protection Fund (IEPF) are not eligible for processing under this facility
• Documentation: Shareholders must contact Alankit Assignments Limited for guidance on required documentation and submission procedures

KYC Updation and Dematerialization Process

Shareholders holding physical shares are requested to update their KYC details using forms available at the company's investor portal. The required information includes PAN, Demat Account Number, Bank Account Number, Email ID, Mobile Number, and Nominee information.

For dematerialized shareholdings, investors must contact their respective Depository Participant (DP) to complete KYC updates. The company strongly encourages conversion of physical share certificates to dematerialized form for enhanced security and easier processing.

The disclosure was signed by Naresh Kapoor, Company Secretary (Membership No: A11782), and dated April 29, 2026. All information is also available on the company's website at www.jubilantpharmova.com .

Jubilant Pharmova Limited has announced an earnings webinar scheduled for May 22, 2026, to discuss the financial performance of the company for the financial year 2025-26. The webinar will be conducted from 6:00 pm to 7:00 pm IST, providing investors with insights into the company's operational and financial achievements for the year ended March 31, 2026.

Webinar Details and Schedule

The earnings webinar has been organized under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparent investor communication.

Registration and Participation Guidelines

Pre-registration is mandatory for the webinar, with investors required to register up to 3 hours before the scheduled call. The webinar will commence with a brief management commentary on the financial performance for the financial year ended March 31, 2026, followed by an interactive Q&A session. Participants may join the queue by clicking the "Raise Hand" icon or post questions through chat during the Q&A session.

Regulatory Compliance and Documentation

The presentation made at the webinar will be submitted to the stock exchange before the event and hosted on the company's official website at www.jubilantpharmova.com for broader accessibility. The formal intimation was signed by Naresh Kapoor, Company Secretary, on April 24, 2026, ensuring compliance with disclosure obligations under the Listing Regulations.

Company Background and Operations

Jubilant Pharmova Limited operates as a global pharmaceutical company with diverse business segments including Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. The company maintains a network of 45 radiopharmacies in the US and operates multiple manufacturing facilities serving regulated markets including USA, Europe and other geographies, with approximately 5,500 employees worldwide.